
    
      The study is an open-label study of 3-years duration. This study will be conducted at 4 study
      sites in Sydney, Australia. Sixteen participants will be recruited comprising 8 participants
      diagnosed with primary HIV infection (Cohort A) and 8 individuals with chronic HIV infection
      (Cohort B). All patients must be antiretroviral therapy (ART) na√Øve and will commence a
      regimen of combination ART consisting of tenofovir disoproxil fumarate and emtricitabine
      (TDF/FTC; Truvada) plus the integrase inhibitor, raltegravir. Subjects will be followed for
      three years with intensive quantification of both plasma RNA and cell associated DNA viral
      species.
    
  